期刊
SCIENTIFIC REPORTS
卷 12, 期 1, 页码 -出版社
NATURE PORTFOLIO
DOI: 10.1038/s41598-022-14523-0
关键词
-
资金
- National Science and Technology Major Project [2017ZX10202102-007]
- Ministry of Science and Technology of the People's Republic of China-Key Program for International S&T Cooperation Projects of China at Wuhan University of Science and Technology [2017YFE0129100]
- Wuhan Science and Technology Plan Project [2019030703011533]
- Postdoctoral Science Foundation of China [2020M682491]
- National Natural Science Foundation of China [82100193]
- Wuhan former funded science and technology program [2020020602012111]
- department of Science and Technology of Hubei Province [2020BCB048]
CAR T-cell therapy is a safe and effective treatment for patients with Hodgkin lymphoma and anaplastic large cell lymphoma. In this study, second and third-generation CAR T-cells targeting CD30 were developed and their efficacy and safety were investigated.
CAR T-cell therapy is well tolerated and effective in patients with Hodgkin lymphoma (HL) and anaplastic large cell lymphoma (ALCL). However, even second- generation anti-CD30 CAR T-cells with CD28 (28z) costimulatory domains failed to achieve the desired rate of complete responses. In the present study, we developed second-generation (CD28z) and third-generation (CD28BBz) CAR T-cells targeting CD30 and investigated their efficacy in vitro and in vivo. Both of CD28z and CD28BBz anti-CD30 CAR T cells were similar regarding amplification, T cell subsets distribution, T cell activity, effector/memory and exhaustion. However, we found that the 28BBz anti-CD30 CAR T-cells persist long-term, specifically homing to the tumor and mediating powerful antitumor activity in tumor xenograft models. Subsequently, we also demonstrated that the third generation anti-CD30 CAR T-cells have miner side effects or potential risks of tumorigenesis. Thus, anti-CD30 CAR T-cells represent a safe and effective treatment for Hodgkin lymphoma.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据